ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologists perspective after publication of the results of ONTARGET

Therapeutic Advances in Cardiovascular Disease

Volumn 2, Issue 4, 2008, Pages 233-248

  Schindler, Christoph ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

ACE Inhibitors; Angiotensin II; Angiotensin Receptor Blockers; Arterial Hypertension; Combination Treatment; Pharmacology

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL; TELMISARTAN; 1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ALISKIREN; AMLODIPINE PLUS BENAZEPRIL; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE; ANTIHYPERTENSIVE AGENT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; ENALAPRIL; LOSARTAN; ORAL ANTIDIABETIC AGENT; PLACEBO; POTASSIUM; VALSARTAN;

ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASE; DRUG COMBINATION; EDITORIAL; HUMAN; KIDNEY DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ANTIHYPERTENSIVE ACTIVITY; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL PHARMACOLOGY; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIABETIC PATIENT; DIALYSIS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PREFERENCE; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; IN-STENT RESTENOSIS; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MONOTHERAPY; NONHUMAN; PATIENT MONITORING; PATIENT SELECTION; POTASSIUM BLOOD LEVEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; PUBLICATION; RISK BENEFIT ANALYSIS; RISK REDUCTION; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARTERIOSCLEROSIS; BENZIMIDAZOLES; BENZOATES; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; HUMANS; KIDNEY DISEASES; RAMIPRIL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 59649122703     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944708094309     Document Type: Editorial

References (107)

1. Abadir, P.M., Carey, R.M. and Siragy, H.M. (2003)Angiotensin AT 2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice. Hypertension 42: 600-604.
2. Aire-Study-Investigators (1993)Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 342: 821-828.
3. Anderson, C. (2005)Rationale and design of the cardiac magnetic resonance imaging substudy of The ONTARGET Trial Programme. J Int Med Res 33 (Suppl 1): 50A-57A.
4. Barnett, A.H., Bain, S.C., Bouter, P., Karlberg, B., Madsbad, S., Jervell, J.et al. (2004)Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351: 1952-1961.
5. Benter, I.F., Yousif, M.H., Anim, J.T., Cojocel, C. and Diz, D.I. (2006)Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am J Physiol Heart Circ Physiol 290: H684-H691
6. Benter, I.F., Yousif, M.H., Cojocel, C., Al-Maghrebi, M. and Diz, D.I. (2007)Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am J Physiol Heart Circ Physiol 292: H666-H672
7. Bohm, M. (2007)Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now? Am J Cardiol 100: 38J-44J.
8. Bonner, G., Preis, S., Schunk, U., Toussaint, C. and Kaufmann, W. (1990)Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J Cardiovasc Pharmacol 15 (Suppl 6): S46-S56.
9. Braunwald, E., Domanski, M.J., Fowler, S.E., Geller, N.L., Gersh, B.J., Hsia, J., et al. (2004)Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351: 2058-2068.
10. Brenner, B.M., Cooper, M.E., de Zeeuw, D., Keane, W.F., Mitch, W.E., Parving, H.H., et al. (2001)Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869.
11. Brillante, D.G., Johnstone, M.T. and Howes, L.G. (2005)Effects of intravenous PD 123319 on haemodynamic and arterial stiffness indices in healthy volunteers. J Renin Angiotensin Aldosterone Syst 6: 102-106.
12. Brillante, D.G., O'sullivan, A.J., Johnstone, M.T. and Howes, L.G.(2008 a)Arterial stiffness and haemodynamic response to vasoactive medication in subjects with insulin-resistance syndrome. Clin Sci (Lond) 114: 139-147.
13. Brillante, D.G., O'sullivan, A.J., Johnstone, M.T. and Howes, L.G.(2008 b)Evidence for functional expression of vascular angiotensin II type 2 receptors in patients with insulin resistance. Diabetes Obes Metab 10: 143-150.
14. Brunner, H., Cockcroft, J.R., Deanfield, J., Donald, A., Ferrannini, E., Halcox, J.et al. (2005)Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 23: 233-246.
15. Burnier, M. and Brunner, H.R. (1999)Comparative antihypertensive effects of angiotensin II receptor antagonists. J Am Soc Nephrol 10 (Suppl 12): S278-S282.
16. Burnier, M. and Brunner, H.R. (2000)Angiotensin II receptor antagonists. Lancet 355: 637-645.
17. Burnier, M. and Maillard, M. (2001)The comparative pharmacology of angiotensin II receptor antagonists. Blood Press (Suppl 1): 6-11.
18. Carey, R.M. (2005)Update on the role of the AT 2 receptor. Curr Opin Nephrol Hypertens 14: 67-71.
19. Cohn, J.N. and Tognoni, G. (2001)A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667-1675.
20. Consensus-Trial-Study-Group (1987)Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316: 1429-1435.
21. Dahlof, B., Devereux, R.B., Kjeldsen, S.E., Julius, S., Beevers, G., de Faire, U.et al. (2002)Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995-1003.
22. Dendorfer, A., Dominiak, P. and Schunkert, H. (2005)ACE inhibitors and angiotensin II receptor antagonists. Handb Exp Pharmacol 407-442.
23. Diamant, M. and Vincent, H.H. (1999)Lisinopril versus enalapril: evaluation of trough:peak ratio by ambulatory blood pressure monitoring. J Hum Hypertens 13: 405-412.
24. Dickstein, K. and Kjekshus, J. (2002)Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360: 752-760.
25. Doran, D.E., Weiss, D., Zhang, Y., Griendling, K.K. and Taylor, W.R. (2007)Differential effects of AT 1 receptor and Ca2+ channel blockade on atherosclerosis, inflammatory gene expression, and production of reactive oxygen species. Atherosclerosis 195: 39-47.
26. Doulton, T.W., He, F.J. and Macgregor, G.A. (2005)Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 45: 880-886.
27. Elliott, W.J. (2000)Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Curr Hypertens Rep 2: 402-411.
28. Feldman, A.M., Koch, W.J. and Force, T.L. (2007)Developing strategies to link basic cardiovascular sciences with clinical drug development: another opportunity for translational sciences. Clin Pharmacol Ther 81: 887-892.
29. Ferrari, P., Marti, H.P., Pfister, M. and Frey, F.J. (2002)Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens 20: 125-130.
30. Ferrario, C.M. (2006)Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst 7: 3-14.
31. Ferrario, C.M., Jessup, J., Chappell, M.C., Averill, D.B., Brosnihan, K.B., Tallant, E.A.et al. (2005 a)Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111: 2605-2610.
32. Ferrario, C.M., Jessup, J., Gallagher, P.E., Averill, D.B., Brosnihan, K.B., Ann Tallant, E.et al. (2005 b)Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int 68: 2189-2196.
33. Ferrario, C.M., Richmond, R.S., Smith, R., Levy, P., Strawn, W.B. and Kivlighn, S. (2004)Renin-angiotensin system as a therapeutic target in managing atherosclerosis. Am J Ther 11: 44-53.
34. Ferrario, C.M., Trask, A.J. and Jessup, J.A.(2005 c)Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 289: H2281-H2290
35. Fogari, R., Derosa, G., Zoppi, A., Preti, P., Lazzari, P., Destro, M.et al. (2007)Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am J Hypertens 20: 417-422.
36. Fox, K.M. (2003)Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362: 782-788.
37. Garg, R. and Yusuf, S. (1995)Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. Jama 273: 1450-1456.
38. Gilles, R., Vingerhoedt, N., Howes, J., Griffin, M. and Howes, L.G. (2004)Increase in systemic blood pressure during intra-arterial PD 123319 infusion: evidence for functional expression of angiotensin type 2 receptors in normal volunteers. Blood Press 13: 110-114.
39. Gottlieb, S.S., Dickstein, K., Fleck, E., Kostis, J., Levine, T.B., Lejemtel, T.et al. (1993)Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 88: 1602-1609.
40. Granger, C.B., Mcmurray, J.J., Yusuf, S., Held, P., Michelson, E.L., Olofsson, B.et al. (2003)Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362: 772-776.
41. Gross, M.L., Adamczak, M. and Ritz, E. (2005)Renal failure and ACE inhibition: how much is too much ? Z Kardiol 94: 81-86.
42. Hasler, C., Nussberger, J., Maillard, M., Forclaz, A., Brunner, H.R. and Burnier, M. (2005)Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor. Clin Pharmacol Ther 78: 501-507.
43. Hunt, S.A. (2005) ACC / AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing
44. Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46: e1-e82.
45. Igase, M., Strawn, W.B., Gallagher, P.E., Geary, R.L. and Ferrario, C.M. (2005)Angiotensin II AT 1 receptors regulate ACE 2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 289: H1013-H1019
46. Ishiyama, Y., Gallagher, P.E., Averill, D.B., Tallant, E.A., Brosnihan, K.B. and Ferrario, C.M. (2004)Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 43: 970-976.
47. Iwanaga, T., Sato, M., Maeda, T., Ogihara, T. and Tamai, I. (2007)Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther 320: 211-217.
48. Iyer, S.N., Ferrario, C.M. and Chappell, M.C. (1998)Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 31: 356-361.
49. Jamerson, K. (2008) Avoiding cardiovascular events through combination therapy in patients living with systolic hypertension, the early termination of the ACCOMPLISH trial.ACC 2008.Chicago.
50. Jessup, J., Gallagher, P.E., Averill, D.B., Brosnihan, K.B., Tallant, E.A., Chappell, M.et al. (2006)Effect of Angiotensin II Blockade on a New Congenic Model of Hypertension Derived from Transgenic Ren-2 Rats. Am J Physiol Heart Circ Physiol Epub. 291: H2166-H2172
51. Johansson, M.E., Fagerberg, B. and Bergstrom, G. (2008)Angiotensin type 2 receptor is expressed in human atherosclerotic lesions. J Renin Angiotensin Aldosterone Syst 9: 17-21.
52. Johnston, G.D. (1992)Dose-response relationships with antihypertensive drugs. Pharmacol Ther 55: 53-93.
53. Julius, S., Kjeldsen, S.E., Weber, M., Brunner, H.R., Ekman, S., Hansson, L.et al. (2004)Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363: 2022-2031.
54. Karalliedde, J. and Viberti, G. (2006)Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes. J Hum Hypertens 20: 239-253.
55. Kober, L., Torp-Pedersen, C., Carlsen, J.E., Bagger, H., Eliasen, P., Lyngborg, K.et al. (1995)A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333: 1670-1676.
56. Koka, V., Huang, X.R., Chung, A.C., Wang, W., Truong, L.D. and Lan, H.Y. (2008)Angiotensin II Up-Regulates Angiotensin I-Converting Enzyme (ACE), but Down-Regulates ACE 2 via the AT1-ERK/p38 MAP Kinase Pathway. Am J Pathol 172: 1174-83.
57. Komine, N., Khang, S., Wead, L.M., Blantz, R.C. and Gabbai, F.B. (2002)Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels. Am J Kidney Dis 39: 159-164.
58. Lewis, E.J., Hunsicker, L.G., Clarke, W.R., Berl, T., Pohl, M.A., Lewis, J.B.et al. (2001)Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860.
59. Li, P., Fukuhara, M., Diz, D.I., Ferrario, C.M. and Brosnihan, K.B. (2000)Novel angiotensin II AT (1) receptor antagonist irbesartan prevents thromboxane A (2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation. J Pharmacol Exp Ther 292: 238-246.
60. Lindholm, L.H., Ibsen, H., Dahlof, B., Devereux, R.B., Beevers, G., de Faire, U.et al. (2002)Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 1004-1010.
61. Lithell, H., Hansson, L., Skoog, I., Elmfeldt, D., Hofman, A., Olofsson, B.et al. (2003)The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21: 875-886.
62. Mcmurray, J.J., Ostergren, J., Swedberg, K., Granger, C.B., Held, P., Michelson, E.L.et al. (2003)Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362: 767-771.
63. Meredith, P. (2000)Achieving quality 24-h blood pressure control with candesartan cilexetil. Blood Press (Suppl 1): 23-26.
64. Meredith, P.A. (2001) Clinical comparative trials of angiotensin II type 1 (AT1)-receptor blockers.Blood Press(Suppl): 11-17.
65. Monton, M., Jimenez, A., Nunez, A., Lopez-Blaya, A., Farre, J., Gomez, J.et al. (2000)Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation. J Cardiovasc Pharmacol 35: 906-913.
66. Mori-Takeyama, U., Minatoguchi, S., Murata, I., Fujiwara, H., Ozaki, Y., Ohno, M.et al. (2008)Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis. Clin Exp Nephrol 12: 33-40.
67. Mueller, C.F. and Nickenig, G. (2008)Angiotensin II: one driving force behind atherogenesis. Hypertension 51: 175-176.
68. Nakao, N., Yoshimura, A., Morita, H., Takada, M., Kayano, T. and Ideura, T. (2003)Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361: 117-124.
69. Ogihara, T., Saruta, T., Shimamoto, K., Matsuoka, H. and Rakugi, H. (2008)Clinical efficacy of a new angiotensin II type 1 receptor blocker, pratosartan, in hypertensive patients. Hypertens Res 31: 281-287.
70. Ontarget-Investigators (2008)Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. N Engl J Med 358: 1547-59.
71. Parving, H.H., Lehnert, H., Brochner-Mortensen, J., Gomis, R., Andersen, S. and Arner, P. (2001)The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878.
72. Pfeffer, M.A., Mcmurray, J.J., Velazquez, E.J., Rouleau, J.L., Kober, L., Maggioni, A.P.et al. (2003)Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893-1906.
73. Phillips, C.O., Kashani, A., Ko, D.K., Francis, G. and Krumholz, H.M. (2007)Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 167: 1930-1936.
74. Phoon, S. and Howes, L.G. (2001)Role of angiotensin type 2 receptors in human forearm vascular responses of normal volunteers. Clin Exp Pharmacol Physiol 28: 734-736.
75. Phoon, S. and Howes, L.G. (2002)Forearm vasodilator response to angiotensin II in elderly women receiving candesartan: role of AT (2)-receptors. J Renin Angiotensin Aldosterone Syst 3: 36-39.
76. Pilote, L., Abrahamowicz, M., Eisenberg, M., Humphries, K., Behlouli, H. and Tu, J.V. (2008)Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. Cmaj 178: 1303-1311.
77. Porogress-Study-Investigators (2001)Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033-1041.
78. Rossing, K., Jacobsen, P., Pietraszek, L. and Parving, H.H. (2003)Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 26: 2268-2274.
79. Ruilope, L.M., Redon, J. and Schmieder, R. (2007)Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme. Vasc Health Risk Manag 3: 1-9.
80. Rutherford, J.D., Pfeffer, M.A., Moye, L.A., Davis, B.R., Flaker, G.C., Kowey, P.R.et al. (1994)Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation 90: 1731-1738.
81. Santos, R.A., Ferreira, A.J. and Simoes, E.S.A.C. (2008)Recent advances in the ACE2-Ang-(1-7)-Mas axis. Exp Physiol 93: 519-27.
82. Savoia, C., Touyz, R.M., Volpe, M. and Schiffrin, E.L. (2007)Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension 49: 341-346.
83. Schindler, C., Bramlage, P., Kirch, W. and Ferrario, C.M.(2007 a)Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. Vasc Health Risk Manag 3: 125-137.
84. Schindler, C., Brosnihan, K.B., Ferrario, C.M., Bramlage, P., Maywald, U., Koch, R.et al. (2007 b)Comparison of inhibitory effects of irbesartan and atorvastatin treatment on the renin angiotensin system (RAS) in veins: a randomized double-blind crossover trial in healthy subjects. J Clin Pharmacol 47: 112-120.
85. Schindler, C., Mueller, A., Bramlage, P., Boecking, W., Kirch, W. and Schweizer, J.(2007 c)Comparison of selective AT1-receptor blockade versus ACE inhibition for restenosis prophylaxis in patients with peripheral occlusive arterial disease after stent angioplasty: a randomized, controlled, proof-of-concept study. Angiology 58: 710-716.
86. Schrader, J., Luders, S., Kulschewski, A., Hammersen, F., Plate, K., Berger, J.et al. (2005)Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36: 1218-1226.
87. Shargorodsky, M., Hass, E., Boaz, M., Gavish, D. and Zimlichman, R. (2008)High dose treatment with angiotensin II receptor blocker in patients with hypertension: differential effect of tissue protection versus blood pressure lowering. Atherosclerosis 197: 303-310.
88. Sica, D.A. (2007)Combination ACE inhibitor and angiotensin receptor blocker therapy-future considerations. J Clin Hypertens (Greenwich) 9: 78-86.
89. Solomon, S.D., Appelbaum, E., Manning, W.J., Verma, A., Berglund, T., Lukashevich, V.et al. (2008) Effect of the Direct Renin Inhibitor Aliskiren, either alone or in combination with losartan, compared to losartan, on left ventricular mass in patients with hypertension and left ventricular hypertrophy: The ALiskiren Left Ventricular Assessment of HypertrophY Trial (ALLAY).American College of Cardiology.
90. Solvd-Investigators (1991)Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 325: 293-302.
91. Staessen, J.A., Li, Y. and Richart, T. (2006)Oral renin inhibitors. Lancet 368: 1449-1456.
92. Strawn, W.B., Chappell, M.C., Dean, R.H., Kivlighn, S. and Ferrario, C.M. (2000)Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 101: 1586-1593.
93. Teo, K., Yusuf, S., Sleight, P., Anderson, C., Mookadam, F., Ramos, B.et al. (2004)Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial / Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 148: 52-61.
94. Toto, R. and Palmer, B.F. (2007)Rationale for Combination Angiotensin Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor Treatment and End-Organ Protection in Patients with Chronic Kidney Disease. Am J Nephrol 28: 372-380.
95. Tran, D., Phoon, S. and Howes, L. (2001)The effects of candesartan on vascular responses to angiotensin II and norepinephrine in normal volunteers. J Renin Angiotensin Aldosterone Syst 2: 199-203.
96. Trask, A.J., Averill, D.B., Ganten, D., Chappell, M.C. and Ferrario, C.M. (2007)Primary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(1-7) in transgenic Ren-2 hypertensive rats. Am J Physiol Heart Circ Physiol 292: H3019-H3024
97. Unger, T. (1999)Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different? Am J Cardiol 84: 9S-15S.
98. Unger, T. (2002)The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 89: 3A-9A; discussion 10A.
99. Urata, H., Nishimura, H. and Ganten, D. (1995)Mechanisms of angiotensin II formation in humans. Eur Heart J, 16 (Suppl N): 79-85.
100. van de Wal, R.M., van der Harst, P., Wagenaar, L.J., Wassmann, S., Morshuis, W.J., Nickenig, G.et al. (2007)Angiotensin II type 2 receptor vasoactivity in internal mammary arteries of patients with coronary artery disease. J Cardiovasc Pharmacol 50: 372-379.
101. Vogt, L., Navis, G. and de Zeeuw, D. (2005)Individual titration for maximal blockade of the renin-angiotensin system in proteinuric patients: a feasible strategy ? J Am Soc Nephrol 16 (Suppl 1): S53-S57.
102. Wassmann, S. and Nickenig, G. (2006)Pathophysiological regulation of the AT1-receptor and implications for vascular disease. J Hypertens (Suppl) 24: S15-S21.
103. Wehling, M. (2006)Translational medicine: can it really facilitate the transition of research “from bench to bedside “? Eur J Clin Pharmacol 62: 91-95.
104. Weiss, D. and Taylor, W.R. (2008)Deoxycorticosterone acetate salt hypertension in apolipoprotein E-/- mice results in accelerated atherosclerosis: the role of angiotensin II. Hypertension 51: 218-224.
105. Wong, M., Staszewsky, L., Latini, R., Barlera, S., Volpi, A., Chiang, Y.T.et al. (2002)Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 40: 970-975.
106. Young, C.L., Dias, V.C. and Stangier, J. (2000)Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects. J Clin Pharmacol 40: 1323-1330.
107. Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R. and Dagenais, G. (2000)Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 145-153.